Adlai Nortye announces pipeline updates

Pipeline updates AN2025: The Company is conducting BURAN, The Company remains on track to present overall survival data in the first quarter of 2025. AN4005: In an ongoing Phase 1 study, the Company is investigating the safety of AN4005, its oral small-molecule PD-L1 inhibitor. The Company plans to provide a clinical update in the second half of 2024. The expansion cohort portion of the trial for IO treatment-naive patients was initiated in July 2024. AN8025: AN8025 is an in-house developed multifunctional fusion protein, which serves as a T cell and APC modulator. The Company anticipates submitting the investigational drug application in mid-2025. AN9025:AN9025 is an in-house developed oral small molecule pan-RAS inhibitor. The Company anticipates submitting the IND in the second half of 2025.